Corvus Pharmaceuticals (CRVS) Treasury Shares (2015 - 2024)

Corvus Pharmaceuticals' (CRVS) quarterly Treasury Shares came in at $400000.0 in Q3 2024, little changed quarter-over-quarter from $400000.0 in Q2 2024.

Corvus Pharmaceuticals (CRVS) Treasury Shares (2015 - 2024) Analysis & Trends

Corvus Pharmaceuticals' Treasury Shares history runs 7 years deep, the most recent figure standing at $400000.0 for Q3 2024.

  • On a quarterly basis, Treasury Shares changed N/A year-over-year to $400000.0 in Q3 2024; TTM through Sep 2024 was $400000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $400000.0, changed N/A from the prior year.
  • Treasury Shares steadied at $400000.0 in Q3 2024 per CRVS's latest filing, from $400000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $400000.0 in Q4 2023 and bottomed at $400000.0 in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Treasury Shares (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -21,709.08
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 265,401.92
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 19.41 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 5.14 Mn
10 Corvus Pharmaceuticals 1.23 Bn 1.23 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2024 400,000.00
Sep 30, 2024 400,000.00
Jun 30, 2024 400,000.00
Jun 30, 2024 400,000.00
Dec 31, 2023 400,000.00
Dec 31, 2023 400,000.00
Jun 30, 2019 12,384.00
Jun 30, 2019 12,384.00
Mar 31, 2019 27,073.00
Mar 31, 2019 27,073.00
Dec 31, 2018 43,076.00
Dec 31, 2018 43,076.00
Sep 30, 2018 99,831.00
Sep 30, 2018 99,831.00
Jun 30, 2018 172,955.00
Jun 30, 2018 172,955.00
Mar 31, 2018 246,079.00
Mar 31, 2018 246,079.00
Dec 31, 2017 319,203.00
Dec 31, 2017 319,203.00